Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 443

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 443
---
 fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY. Tammy Galili, Director Tammy Galili has served as a director at Kadimastem since July 2021. She has three decades of experience in various management positions in the pharmaceutical space. She served as the CEO of Ilex Medical Ltd. from January 2016 and until October 2024, and previously served as the company’s Deputy CEO from January 2014 until January 2014, and Vice President of Sales and Marketing from January 2010 until December 2013. Ms. Galili has an MBA in Healthcare Innovation from Reichman University in Herzliya and a BA in Philosophy and History of the Middle East in Modern Times from the Tel Aviv University. Family Relationships Mr.Ariel Revel, Director of Medical Affairs of the combined company, is the son of Professor Michel Revel, Chief Scientific Officer and director of the combined company. Director Independence Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren are the independent directors of Kadimastem. Kadimastem’s board of directors has determined that all of its current independent directors are independent, as determined in accordance with the rules of The Nasdaq Stock Market. Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren as members of each of the Audit, Compensation, Nomination and Governance Committees for a term lasting until the next annual ordinary shareholders’ meeting. 251 The Kadimastem board of directors has also determined that each current member of the compensation committee is independent as defined under Nasdaq listing standards and the Israel Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq listing standards and applicable SEC rules and Israel Companies laws. Board Committees Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren as members of each of the Audit, Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. The Kadimastem board of directors has determined that each current member of the compensation committee is independent as defined under Nasdaq listing standards and the Israel Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq listing standards and applicable SEC rules and Israel